Could a cholesterol drug and antioxidant help treat a rare bleeding disorder?
NCT ID NCT07662525
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial investigates whether combining atorvastatin (a cholesterol-lowering drug), N-acetyl-L-cysteine (an antioxidant), and romiplostim (a platelet-boosting drug) can help adults with immune thrombocytopenia (ITP) who no longer respond to steroids. The goal is to see if this approach can keep platelet counts stable even after stopping all treatments. Fifty participants will receive the combination for 24 weeks, followed by a gradual taper of romiplostim, and will be monitored for sustained response off-treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atorvastatin, N-acetyl-L-cysteine, and romiplostim
- What this could lead to
- If successful, this combination could help people with hard-to-treat immune thrombocytopenia maintain safe platelet levels without needing long-term medication.
- What could go wrong
- This is a small, single-center study with no control group, so results may not apply broadly. The treatment involves multiple drugs and close monitoring, and some participants may not respond or may experience side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug calm the immune System's attack on blood cells?
- Double attack on blood disorder: could two drugs beat one for stubborn ITP?
- New hope for lupus patients with dangerous low platelet counts
- Can a simple blood test predict who will get chronic ITP?
- New shot aims to boost platelets in bleeding disorder
- New drug IASO-782 aims to tame immune attacks on blood cells